Vaccine Type: Non Replicating Viral Vector
This vaccine has reached Phase 2 trials.
About Trial Phases
There are no trials for this phase.
This vaccine is not yet approved.
Total Enrollment: 420
Total Enrollment: 400
© 2022 VIPER Group COVID19 Vaccine Tracker Team
Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)
This site is provided for informational purposes only based on publically available data.
Site Credits | Website Feedback Form